Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim

Risk and Timing of Neutropenic Events in Adult Cancer Patients Receiving Chemotherapy: The Results of a Prospective Nationwide Study of Oncology Practice

(2017) Jeffrey Crawford et al.   Journal of the National Comprehensive Cancer Network

The five “Ws” for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs)

(2013) Matteo Lambertini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Prevention of Pegfilgrastim-Induced Bone Pain: A Phase III Double-Blind Placebo-Controlled Randomized Clinical Trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base

(2012) Jeffrey J. Kirshner et al.   JOURNAL OF CLINICAL ONCOLOGY

A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy

(2010) J. Randolph Hecht et al.   Clinical Colorectal Cancer

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

(2010) M.S. Aapro et al.   EUROPEAN JOURNAL OF CANCER

Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non–Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies

(2010) Howard A. Burris et al.   Journal of Oncology Practice

Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen

(2009) Rodolfo Mattioli et al.   Clinical & Translational Oncology